Table 3.
Laboratory findings, treatment throughout hospitalization, and outcomes of children with MIS-C.
| Laboratory results, median (IQR) | |
|---|---|
| WBC count (cells × 103/μL) | 9.33 (2.58‒28.14) |
| Absolute lymphocyte count (cells × 103/μL) | 0.85 (0.13‒3.84) |
| C-reactive protein (mg/L) | 170 (11.5‒375) |
| D-dimer (mg/L) | 3.41 (0.18‒36.48) |
| Albumin (g/L) | 30.2 (19.5‒43.4) |
| Ferritin (μg/L) | 327.2 (23.2‒11981) |
| Procalcitonin (μg/L) | 3.88 (0.12‒185) |
| Pro BNP (ng/L) | 1538 (9.62‒39880) |
| Troponin (ng/L) | 9.39 (3‒800.6) |
| Sodyum (mEq/L) | 133 (126‒143) |
| Treatment, n (%) | |
| Acetylsalicylic acid | 39 (90.7%) |
| Intravenous immunoglobulin | 33 (76.7%) |
| Systemic corticosteroids | 35 (81.4%) |
| Plasmapheresis | 1 (2.3%) |
| Clinical outcome, n (%) | |
| MIS-C severity, n (%) | |
| Mild | 24 (55.8%) |
| Moderate | 9 (20.9%) |
| Severe | 10 (23.3%) |
| Hospitalization in the ICU, n (%) | 19 (44.2%) |
| Days of hospitalization, median | 7 (1‒53) |
| Days of ICU, median | 3 (1‒7) |
| Oxygen | 12 (27.9%) |
| Invasive mechanical ventilation | 3 (6.9%) |
| ECMO | 1 (2.3%) |
| Vasoactive drugs | 20 (46.5%) |
| Death | 2 (4.7%) |